Table 1.
Patient Characteristics and Development of Cataract and/or Dry Eye Syndrome
| Variable | All | Cataract | No Cataract | Pa | Dry Eye | No Dry Eye | P |
|---|---|---|---|---|---|---|---|
| Age at Transplant (yrs) | |||||||
| 0.0023 | 0.0067 | ||||||
| Mean (SDb) | 13.41 (3.74) | 14.07 (3.61) | 12.21 (3.7) | 12.93 (3.68) | 14.46 (3.67) | ||
| Median (range) | 13.57 (7.06–25.16) | 14.4 (7.38–25.16) | 12.52 (7.06–21.17) | 12.94 (7.06–25.16) | 15.21 (7.17–21.07) | ||
| Age at Cancer Diagnosis (yrs) | |||||||
| 0.034 | 0.42 | ||||||
| Mean (SD) | 10.24 (5.45) | 10.77 (5.75) | 9.25 (4.75) | 10.12 (5.2) | 10.48 (6.02) | ||
| Median (range) | 11.8 (0–18.8) | 12.82 (0–18.8) | 9 (0–18.44) | 10.66 (0–18.8) | 12.63 (0–18.14) | ||
| Total Body Irradiation Dosec (cGy) | |||||||
| <0.001 | 0.29 | ||||||
| Mean (SD) | 782.72 (606.96) | 600 (615.19) | 1119.3 (422.34) | 807.21 (605.99) | 729.41 (611.65) | ||
| Median (range) | 1200 (0–1400) | 200 (0–1400) | 1200 (0–1400) | 1200 (0–1400) | 1200 (0–1400) | ||
| Head/Neck Radiation Dose (cGy) | |||||||
| 0.097 | 0.95 | ||||||
| Mean (SD) | 137.96 (634.83) | 110.86 (656.94) | 187.89 (594.36) | 115.41 (467.17) | 187.06 (902.21) | ||
| Median (range) | 0 (0–5940) | 0 (0–5940) | 0 (0–2550) | 0 (0–2550) | 0 (0–5940) | ||
| Non-Head/Neck Radiation Dose (cGy) | |||||||
| 0.71 | 0.82 | ||||||
| Mean (SD) | 130.56 (336.6) | 119.05 (304.48) | 151.75 (390.97) | 132.88 (349.84) | 125.49 (309.09) | ||
| Median (range) | 0 (0–2100) | 0 (0–2100) | 0 (0–1950) | 0 (0–2100) | 0 (0–1500) | ||
| Gender (number, %) | |||||||
| 0.41 | 0.61 | ||||||
| Female | 67 (41.36) | 46 (43.81) | 21 (36.84) | 44 (39.64) | 23 (45.1) | ||
| Male | 95 (58.64) | 59 (56.19) | 36 (63.16) | 67(60.36) | 28 (54.9) | ||
| Race (number, %) | |||||||
| 0.0049 | 0.49 | ||||||
| Black | 28 (17.28) | 25 (23.81) | 3 (5.26) | 19 (17.12) | 9 (17.65) | ||
| Other | 24 (14.81) | 16 (15.24) | 8 (14.04) | 14 (12.61) | 10 (19.61) | ||
| White | 110 (67.9) | 64 (60.95) | 46 (80.7) | 78 (70.27) | 32 (62.75) | ||
| Diagnosis (number, %) | |||||||
| <0.001 | 1 | ||||||
| Hematologic malignancy | 121 (74.69) | 68 (64.76) | 53 (92.98) | 83 (74.77) | 38 (74.51) | ||
| Nonmalignant disease | 41 (25.31) | 37 (35.24) | 4 (7.02) | 28 (25.23) | 13 (25.49) | ||
| Donor Type (number, %) | |||||||
| 0.053 | 0.16 | ||||||
| Others | 27 (16.67) | 21 (20) | 6 (10.53) | 16 (14.41) | 11 (21.57) | ||
| Sibling | 67 (41.36) | 47 (44.76) | 20 (35.09) | 43 (38.74) | 24 (47.06) | ||
| Unrelated | 68 (41.98) | 37 (35.24) | 31 (54.39) | 52 (46.85) | 16 (31.37) | ||
| Survival (number, %) | |||||||
| 1 | 0.55 | ||||||
| Alive | 149 (91.98) | 96 (91.43) | 53 (92.98) | 103 (92.79) | 46 (90.2) | ||
| Expired | 13 (8.02) | 9 (8.57) | 4 (7.02) | 8 (7.21) | 5 (9.8) | ||
| Product Type (number, %) | |||||||
| 0.15 | 0.11 | ||||||
| Apheresis | 31 (19.14) | 24 (22.86) | 7 (12.28) | 17 (15.32) | 14 (27.45) | ||
| Cord blood | 2 (1.23) | 2 (1.9) | 0 (0) | 1 (0.9) | 1 (1.96) | ||
| Marrow | 129 (79.63) | 79 (75.24) | 50 (87.72) | 93 (83.78) | 36 (70.59) | ||
| Cytomegalovirus Status of Recipient (number, %) | |||||||
| 0.0082 | 0.74 | ||||||
| Negative | 81 (50) | 44 (41.9) | 37 (64.91) | 57 (51.35) | 24 (47.06) | ||
| Positive | 81 (50) | 61 (58.1) | 20 (35.09) | 54 (48.65) | 27 (52.94) | ||
| Steroid Use (number, %) | |||||||
| 0.048 | 0.026 | ||||||
| No | 115 (70.99) | 69 (65.71) | 46 (80.7) | 85 (76.58) | 30 (58.82) | ||
| Yes | 47 (29.01) | 36 (34.29) | 11 (19.3) | 26 (23.42) | 21 (41.18) | ||
| Calcineurin Inhibitor Use (number, %) | |||||||
| 0.63 | 26 (23.42) | 21 (41.18) | 0.61 | ||||
| No | 21 (12.96) | 15 (14.29) | 6 (10.53) | 16 (14.41) | 5 (9.8) | ||
| Yes | 141 (87.04) | 90 (85.71) | 51 (89.47) | 95 (85.59) | 46 (90.2) | ||
| Presence of Acute Graft-versus-host Disease (number, %) | |||||||
| 0.41 | 0.4 | ||||||
| No | 91 (56.17) | 56 (53.33) | 35 (61.4) | 65 (58.56) | 26 (50.98) | ||
| Yes | 71 (43.83) | 49 (46.67) | 22 (38.6) | 46 (41.44) | 25 (49.02) | ||
| Presence of Chronic Graft-versus-host Disease (number, %) | |||||||
| 0.33 | 0.00046 | ||||||
| No | 125 (77.16) | 78 (74.29) | 47 (82.46) | 95 (85.59) | 30 (58.82) | ||
| Yes | 37 (22.84) | 27 (25.71) | 10 (17.54) | 16 (14.41) | 21 (41.18) | ||
| Use of Total Body Irradiation (number, %) | |||||||
| <0.001 | 0.6 | ||||||
| No | 58 (35.8) | 52 (49.52) | 6 (10.53) | 38 (34.23) | 20 (39.22) | ||
| Yes | 104 (64.2) | 53 (50.48) | 51 (89.47) | 73 (65.77) | 31 (60.78) | ||
| Busulfan Use (number, %) | |||||||
| 0.3 | 0.59 | ||||||
| No | 144 (88.89) | 91 (86.67) | 53 (92.98) | 100 (90.09) | 44 (86.27) | ||
| Yes | 18 (11.11) | 14 (13.33) | 4(7.02) | 11 (9.91) | 7 (13.73) | ||
| Cyclophosphamide Use (number, %) | |||||||
| 0.039 | 0.16 | ||||||
| No | 25 (15.43) | 21 (20) | 4 (7.02) | 14 (12.61) | 11 (21.57) | ||
| Yes | 137 (84.57) | 84 (80) | 53 (92.98) | 97 (87.39) | 40 (78.43) | ||
| Cytarabine Use (number, %) | |||||||
| <0.001 | 0.46 | ||||||
| No | 113 (69.75) | 87 (82.86) | 26 (45.61) | 75 (67.57) | 38 (74.51) | ||
| Yes | 49 (30.25) | 18 (17.14) | 31 (54.39) | 36 (32.43) | 13 (25.49) | ||
| Fludarabine Use (number, %) | |||||||
| 0.0037 | 0.12 | ||||||
| No | 135 (83.33) | 81 (77.14) | 54 (94.74) | 96 (86.49) | 39 (76.47) | ||
| Yes | 27 (16.67) | 24 (22.86) | 3 (5.26) | 15 (13.51) | 12 (23.53) | ||
| Melphalan Use (number, %) | |||||||
| 0.02 | 0.12 | ||||||
| No | 143 (88.27) | 88 (83.81) | 55 (96.49) | 101(90.99) | 42 (82.35) | ||
| Yes | 19 (11.73) | 17 (16.19) | 2 (3.51) | 10(9.01) | 9 (17.65) | ||
| Thiotepa Use (number, %) | |||||||
| 0.091 | 0.49 | ||||||
| No | 102 (62.96) | 61 (58.1) | 41 (71.93) | 72 (64.86) | 30 (58.82) | ||
| Yes | 60 (37.04) | 44 (41.9) | 16 (28.07) | 39 (35.14) | 21 (41.18) | ||
| Conditioning Treatment (number, %) | |||||||
| <0.001 | 0.72 | ||||||
| Chemotherapy/radiation | 104 (64.2) | 53 (50.48) | 51 (89.47) | 73 (65.77) | 31 (60.78) | ||
| None | 14 (8.64) | 13 (12.38) | 1 (1.75) | 10 (9.01) | 4 (7.84) | ||
| Chemotherapy only | 44(27.16) | 39 (37.14) | 5 (8.77) | 28 (25.23) | 16 (31.37) | ||
a
Abbreviations: SD, standard deviation.
b
Statistically significant values are in bold.
c
A value of 0 was given for those patients who did not receive radiation.